KBC Group NV Increases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

KBC Group NV boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 236,318 shares of the specialty pharmaceutical company's stock after purchasing an additional 8,014 shares during the quarter. KBC Group NV owned approximately 0.39% of Jazz Pharmaceuticals worth $29,103,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. CWA Asset Management Group LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $9,335,000. Pacer Advisors Inc. grew its stake in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after acquiring an additional 48,708 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $0.68 during trading on Friday, hitting $124.37. 665,647 shares of the stock traded hands, compared to its average volume of 450,973. The company has a fifty day moving average price of $122.69 and a two-hundred day moving average price of $116.04. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market cap of $7.52 billion, a price-to-earnings ratio of 17.52, a P/E/G ratio of 0.90 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company's stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,253 shares of company stock worth $890,594 in the last ninety days. Company insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on JAZZ shares. TD Cowen lowered their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Morgan Stanley raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Piper Sandler reissued an "overweight" rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.